Source BioScience Acquires Inverclyde Biologicals Limited

Published: Apr 30, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

30 April 2013 -- Source BioScience plc (LSE: SBS), the international diagnostic and genetic analysis services business, announces the acquisition of the entire issued share capital of Inverclyde Biologicals Limited (‘Inverclyde Biologicals’), Motherwell, Scotland for a total consideration of £1.6 million payable in cash.


-- Inverclyde is a market leading manufacturer of high quality diagnostic kits and blood group serology reagents

-- Consideration of £1.6 million; cash acquired with the business of £0.3 million

-- Revenue of £0.7 million; £0.2 million profit before tax and cash generated from operations

-- Complementary with existing Source BioScience healthcare products business with the same high standards for quality and service and a strong reputation within the NHS

-- Creation of new cross-selling opportunities, an extended customer base and better utilisation of existing infrastructure

-- Inverclyde Biologicals’ expertise in designing and manufacturing clinical grade reagents complement the Group’s expansion plans for the reSource™ range of life science products

-- Geographic expansion into Scotland, providing the opportunity to establish an Overnight Service for DNA sequencing accessible by the Scottish research community

-- The current Inverclyde Biologicals directors are both remaining with the Group and bring a well regarded and qualified talent, together with a dedicated, highly skilled and knowledgeable workforce.

Dr Nick Ash, CEO of Source BioScience, said: “The acquisition of Inverclyde Biologicals fits squarely with our stated objective of continued expansion through both targeted acquisitions and development of our existing business. This acquisition provides a platform for increased penetration of the UK healthcare market, acting as a catalyst for our accelerated growth. The Inverclyde Biologicals team will bring significant experience and knowledge to the Group and we will be able to leverage the enlarged Group’s existing links with healthcare providers across the UK and distributor network overseas.”

For further information, please contact:

Source BioScience plc Nick Ash Chief Executive Officer Tel: +44 (0)115 973 9010

For investor and media enquiries:

N+1 Singer (Financial Advisor, Sponsor and Broker) Aubrey Powell/Joe Stroud Tel: +44 (0)207 496 3155

College Hill (PR Agency to Source BioScience) Melanie Toyne-Sewell/Stefanie Bacher Tel: +44 (0)207 457 2020 Mob: +44 (0)7792 693760 Email:

Help employers find you! Check out all the jobs and post your resume.

Back to news